Find Stavudine, Lamivudine, Nevirapine Drug Combination manufacturers, exporters & distributors on PharmaCompass

Stavudine, Lamivudine, Nevirapine Drug Combination

Stavudine, Lamivudine, Nevirapine Drug Combination

Synopsis, Chemistry

DOSSIERs // Finished Dosage Formulations

2 Dossiers, 2 FDA Orange Book

DIGITAL CONTENT

1 News

1 News

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Stavudine, Lamivudine, Nevirapine Drug Combination

Also known as: 811471-91-7, 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one;1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione, Lamivudine; stavudine; nevirapine, Lamivudine/nevirapine/stavudine, Stavudine, lamivudine and nevirapine, Lamivudine mixture with nevirapine and stavudine

Molecular Formula

C₃₃H₃₇N₉O₈S

Molecular Weight

719.8 g/mol

InChI Key

FEOBXHIFUYOHBP-KPTOQMEFSA-N

1 2D Structure

Stavudine, Lamivudine, Nevirapine Drug Combination

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one;1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione

2.1.2 InChI

InChI=1S/C15H14N4O.C10H12N2O4.C8H11N3O3S/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10;1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8;9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h2-3,6-8,10H,4-5H2,1H3,(H,18,20);2-4,7-8,13H,5H2,1H3,(H,11,14,15);1-2,6-7,12H,3-4H2,(H2,9,10,13)/t;7-,8+;6-,7+/m.00/s1

2.1.3 InChI Key

FEOBXHIFUYOHBP-KPTOQMEFSA-N

2.1.4 Canonical SMILES

CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4.CC1=CN(C(=O)NC1=O)C2C=CC(O2)CO.C1C(OC(S1)CO)N2C=CC(=NC2=O)N

2.1.5 Isomeric SMILES

CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4.CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO.C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N

2.2 Synonyms

2.2.1 MeSH Synonyms

1. Stavudine - Lamivudine - Nevirapine

2. Stavudine, Lamivudine, Nevirapine Drug Combination

3. Triomune

2.2.2 Depositor-Supplied Synonyms

1. 811471-91-7

2. 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one;1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione

3. Lamivudine; Stavudine; Nevirapine

4. Lamivudine/nevirapine/stavudine

5. Stavudine, Lamivudine And Nevirapine

6. Lamivudine Mixture With Nevirapine And Stavudine

7. Stv & Lmv & Nvp

8. Lamivudine, Nevirapine, And Stavudine Fixed-dose Tablet

9. Nevirapine & Lamivudine & Stavudine

10. 11-cyclopropyl-4-methyl-5,11-dihydro-6h-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & (-)-(2'r,5's)-1-[2'-hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine & Thymidine, 2',3'-didehydro-, 3'-deoxy-

11. 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; 11-cyclopropyl-4-methyl-5h-dipyrido[[?],[?]][1,4]diazepin-6-one; 1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione

2.3 Create Date

2007-03-19

3 Chemical and Physical Properties

Molecular Formula	C₃₃H₃₇N₉O₈S
Molecular Weight	719.8 g/mol
Hydrogen Bond Donor Count	5
Hydrogen Bond Acceptor Count	12
Rotatable Bond Count	5
Exact Mass	719.24858035 g/mol
Monoisotopic Mass	719.24858035 g/mol
Topological Polar Surface Area	250 Å²
Heavy Atom Count	51
Formal Charge	0
Complexity	1120
Isotope Atom Count	0
Defined Atom Stereocenter Count	4
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	3

4 Drug and Medication Information

4.1 Drug Information

1 of 2
Drug Name	Lamivudine; stavudine; nevirapine
Active Ingredient	stavudine; Lamivudine; nevirapine
Dosage Form	Tablet; Tablet, dispersible
Route	oral
Strength	100mg; 6mg; 30mg; 200mg; 150mg; 12mg; 50mg; 30mg; 40mg; 60mg
Market Status	Tentative Approval
Company	Cipla

2 of 2
Drug Name	Lamivudine; stavudine; nevirapine
Active Ingredient	stavudine; Lamivudine; nevirapine
Dosage Form	Tablet; Tablet, dispersible
Route	oral
Strength	100mg; 6mg; 30mg; 200mg; 150mg; 12mg; 50mg; 30mg; 40mg; 60mg
Market Status	Tentative Approval
Company	Cipla

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Anti-HIV Agents

Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)

Reverse Transcriptase Inhibitors

Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. (See all compounds classified as Reverse Transcriptase Inhibitors.)

5.2 ATC Code

J - Antiinfectives for systemic use

J05 - Antivirals for systemic use

J05A - Direct acting antivirals

J05AR - Antivirals for treatment of hiv infections, combinations

J05AR07 - Stavudine, lamivudine and nevirapine